Takeda Pharmaceutical Co., Ltd. et al v. Impax Laboratories, Inc.,
ORDER re 50 Stipulation of Dismissal of Count XI (False Marking) without prejudice filed by Impax Laboratories, Inc. Motions terminated: 20 MOTION to Dismiss Count XI of Impax's Counterclaims filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals LLC. Signed by Judge Joseph C. Spero on 10/13/11. (klhS, COURT STAFF) (Filed on 10/14/2011)
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN FRANCISCO DIVISION
TAKEDA PHARMACEUTICAL CO., LTD.,
TAKEDA PHARMACEUTICALS NORTH
AMERICA, INC., TAKEDA
PHARMACEUTICALS LLC, AND
Case No. 3:11-cv-01610-JCS
[PROPOSED] ORDER ON STIPULATION
OF DISMISSAL PURSUANT TO FED. R.
CIV. P. 41(a)(1) and (c)
IMPAX LABORATORIES, INC.,
Having considered the parties’ Stipulation of Dismissal of Count XI (False Marking) of
Defendant Impax’s Counterclaims (“Count XI”), IT IS ORDERED that Count XI is hereby
dismissed without prejudice, with each party to bear its own costs.
DATED: __________________, 2011
THE HONORABLE JOSEPH C. SPERO
UNITED STATES MAGISTRATE JUDGE
D IS T IC T O
[PROPOSED] ORDER ON STIPULATION OF
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?